A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. Issue 2 (8th February 2018)

• Record Type: Journal Article
• Authors: Kempker, Russell R.; Heinrichs, M. Tobias; Nikolaishvili, Ketino; Sabulua, Irina; Bablishvili, Nino; Gogishvili, Shota; Avaliani, Zaza; Little, Brent P.; Bernheim, Adam; Derendorf, Hartmut; Blumberg, Henry M.; Vashakidze, Sergo; Peloquin, Charles A.
• Is Part Of: European respiratory journal. Volume 51:Issue 2(2018)
• Publication Date: 2018-02-08
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02166-2017
• Languages: English
• ISSNs: 0903-1936

Abstract

Linezolid has become a frequent component of treatment regimens for drug-resistant tuberculosis and is a group C drug in the latest World Health Organization treatment guidelines [1]. However, linezolid has a narrow therapeutic index and there is no consensus on the optimal dose for patients with tuberculosis [2, 3]. A better understanding of lung tissue penetration could provide insight into ideal dosing and the utility of linezolid in patients with severe lung lesions. To evaluate target site lung concentrations of linezolid, we utilised the technique of microdialysis, which facilitates the measurement of unbound (pharmacologically active) extracellular drug concentrations at the site of disease. Among TB patients undergoing surgical resection, linezolid concentrations in lung tissue were half of serum values http://ow.ly/Anlb30hEpW4